ESR1 and breast carcinoma: Our recent studies have shown that stage II and III high-risk estrogen receptor positive (ER + ) breast cancer cells upregulate growth factor receptors to amplify alternatives to estrogen growth signaling after treatment with endocrine and cell cycle therapy to bypass cell cycle arrest and promote resistance10.